Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accounts Payables: 2020-2025

Historic Accounts Payables for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to $103.5 million.

  • Tarsus Pharmaceuticals' Accounts Payables rose 89.75% to $103.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 89.75%. This contributed to the annual value of $64.8 million for FY2024, which is 173.48% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Accounts Payables of $103.5 million as of Q3 2025, which was up 31.61% from $78.6 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Accounts Payables' 5-year high stood at $103.5 million during Q3 2025, with a 5-year trough of $8.1 million in Q3 2021.
  • Moreover, its 3-year median value for Accounts Payables was $43.5 million (2024), whereas its average is $46.9 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first fell by 16.25% in 2023, then skyrocketed by 360.15% in 2024.
  • Tarsus Pharmaceuticals' Accounts Payables (Quarterly) stood at $8.7 million in 2021, then rose by 14.17% to $9.9 million in 2022, then skyrocketed by 139.06% to $23.7 million in 2023, then spiked by 173.48% to $64.8 million in 2024, then spiked by 89.75% to $103.5 million in 2025.
  • Its Accounts Payables stands at $103.5 million for Q3 2025, versus $78.6 million for Q2 2025 and $76.4 million for Q1 2025.